GLP-1 Vision Loss en Taunton

Lawsuits alleging that GLP-1 drugs caused non-arteritic anterior ischemic optic neuropathy, an eye stroke usually called NAION, are consolidated in their own federal multidistrict litigation, In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL No. 3163, created by the Judicial Panel on Multidistrict Litigation on December 15, 2025 and assigned to Judge Karen S. Marston in the Eastern District of Pennsylvania. That is a separate MDL from the gastrointestinal GLP-1 litigation, MDL No. 3094, before the same judge. The JPML transfer order names Ozempic, Wegovy, Saxenda and Trulicity, so the litigation already reaches liraglutide and dulaglutide and is not limited to semaglutide. Plaintiffs bring failure to warn, design defect and breach of warranty claims against Novo Nordisk and Eli Lilly. The central allegation is a warning gap that can be checked in the documents themselves: the European Medicines Agency concluded on June 6, 2025 that NAION is a very rare side effect of semaglutide and required it on European product information, while the United States prescribing information reviewed for this page does not mention NAION, ischemic optic neuropathy or optic neuropathy anywhere in its 34 pages. The Taunton, Massachusetts theory rests on the implied warranty of merchantability under M.G.L. c. 106 sec. 2-314, the consumer-protection statute at c. 93A, and the three-year deadline in c. 260 sec. 2A, where the discovery rule matters because most patients are never told the drug is a suspect. These matters are accepted on contingency, meaning no attorney's fee unless and until the matter resolves with a recovery to the client; case-related costs and expenses are addressed in the written fee agreement. Call Jim Glaser Law at (617) JIM-WINS. The line is answered 24 hours a day. The first telephone consultation is offered without charge.